Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06120400 · ClinicalTrials.gov registry record · Phase 3
Cardiovascular Effects of a Healthy Dietary Pattern Containing Eggs
A Phase 3 study of Cardiovascular Diseases, sponsored by Penn State University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT06120400 is a Phase 3 study of Cardiovascular Diseases that is actively recruiting participants, run by Penn State University. The registered enrollment target is 65 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06120400, a Phase 3 study of Cardiovascular Diseases, is actively recruiting participants, sponsored by Penn State University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effect of a healthy diet containing 2 eggs per day compared to a healthy diet containing 3 eggs per week on biomarkers of heart health after 4 weeks.
Conditions Studied
Interventions
- DRUG Whole Egg
Study Locations (1)
Pennsylvania
- The Pennylvania State University - University Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2024-04-25 |
| Est. Completion | 2026-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06120400
The ClinicalTrials.gov registry entry for NCT06120400 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Penn State University, which has 219 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Whole Egg is the first listed.
NCT06120400 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06120400 about?
NCT06120400 is a clinical study titled "Cardiovascular Effects of a Healthy Dietary Pattern Containing Eggs". This study will examine the effect of a healthy diet containing 2 eggs per day compared to a healthy diet containing 3 eggs per week on biomarkers of heart health after 4 weeks.
What is the current status of trial NCT06120400?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2024-04-25. Estimated completion is 2026-07.
What conditions does trial NCT06120400 study?
This clinical trial studies the following conditions: Cardiovascular Diseases.
What interventions are being tested in trial NCT06120400?
The interventions under investigation include: Whole Egg (DRUG).
Who is sponsoring clinical trial NCT06120400?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06120400 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of Hematocrit Levels in Infant Heart Surgery
COMPLETED · Phase 3
-
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.